SSY Group Limited Stock

Equities

2005

KYG8406X1034

Pharmaceuticals

Delayed Hong Kong S.E. 03:19:06 2024-07-18 EDT 5-day change 1st Jan Change
4.36 HKD +1.40% Intraday chart for SSY Group Limited +1.16% -11.74%

Financials

Sales 2024 * 7.58B 971M 1.33B Sales 2025 * 8.83B 1.13B 1.55B Capitalization 12.77B 1.64B 2.24B
Net income 2024 * 1.57B 201M 275M Net income 2025 * 1.84B 236M 323M EV / Sales 2024 * 1.68 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.45 x
P/E ratio 2024 *
8.15 x
P/E ratio 2025 *
6.9 x
Employees 5,640
Yield 2024 *
3.95%
Yield 2025 *
4.19%
Free-Float 41.1%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.40%
1 week+1.16%
Current month+3.32%
1 month-8.21%
3 months-6.84%
6 months-5.01%
Current year-11.74%
More quotes
1 week
4.26
Extreme 4.26
4.44
1 month
4.19
Extreme 4.19
4.88
Current year
3.88
Extreme 3.88
5.20
1 year
3.88
Extreme 3.88
5.20
3 years
2.50
Extreme 2.5
6.75
5 years
2.50
Extreme 2.5
9.00
10 years
1.69
Extreme 1.69
9.46
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 -
Director of Finance/CFO 43 15-03-31
Director/Board Member 48 -
Members of the board TitleAgeSince
Chief Executive Officer 67 -
Director/Board Member 59 07-07-25
Director/Board Member 55 05-10-15
More insiders
Date Price Change Volume
24-07-18 4.36 +1.40% 626 000
24-07-17 4.3 +0.23% 732,000
24-07-16 4.29 0.00% 1,066,000
24-07-15 4.29 -0.92% 1,326,000
24-07-12 4.33 +0.46% 878,000

Delayed Quote Hong Kong S.E., July 18, 2024 at 03:19 am

More quotes
SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.3 HKD
Average target price
6.227 HKD
Spread / Average Target
+44.81%
Consensus

Annual profits - Rate of surprise